Big Techs and startups in pharmaceutical R&D - A 2020 perspective on artificial intelligence.

Journal: Drug discovery today
Published Date: May 7, 2021

Abstract

We investigated what kind of artificial intelligence (AI) technologies are utilized in pharmaceutical research and development (R&D) and which sources of AI-related competencies can be leveraged by pharmaceutical companies. First, we found that machine learning (ML) is the dominating AI technology currently used in pharmaceutical R&D. Second, both Big Techs and AI startups are competent knowledge bases for AI applications. Big Techs have long-lasting experience in the digital field and offer more general IT solutions to support pharmaceutical companies in cloud computing, health monitoring, diagnostics or clinical trial management, whereas startups can provide more specific AI services to address special issues in the drug-discovery space.

Authors

  • Alexander Schuhmacher
    Reutlingen University, Alteburgstrasse 150, 72762, Reutlingen, Germany. Electronic address: alexander.schuhmacher@reutlingen-university.de.
  • Alexander Gatto
    Sony Europe B.V., Stuttgart Technology Center, Hedelfinger Strasse 61, DE-70327 Stuttgart, Germany.
  • Michael Kuss
    PricewaterhouseCoopers AG, Birchstrasse 160, 8050, Zürich, Switzerland. Electronic address: michael.kuss@ch.pwc.com.
  • Oliver Gassmann
    University of St. Gallen, Institute of Technology Management, Dufourstrasse 40a, 9000, St. Gallen, Switzerland. Electronic address: oliver.gassmann@unisg.ch.
  • Markus Hinder
    Novartis Institute of BioMedical Research, Postfach, Forum 1, 4002, Basel, Switzerland. Electronic address: markus.hinder@novartis.com.

Keywords

External Resources

Popular Topics
Recent Journals